Finasteride-Induced Pseudoporphyria

Domingo, Diana; Stevenson, Mary L.; Auerbach, Jena; Lerman, Jay S.

doi:10.1001/archdermatol.2011.144

Cited by 16 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiphospholipid syndrome, radiation arteritis, vasculitis, dystrophic calcification, cholesterol emboli, panniculitis, purpura fulminans, warfarin or heparin necrosis, pyoderma gangernosum, and levamisole toxicity should be considered in evaluating retiform purpura (44).…”

Section: Calciphylaxis (Calcific Uremic Arteriolopathy)mentioning

confidence: 99%

“…Development of PP has also been associated with ultraviolet A (UVA) tanning beds, psoralen UVA (PUVA), phototherapy with ultraviolet B (UVB), and medications including diuretics, nonsteroidal antiinflammatory drugs (e.g., naproxen), antibiotics, antifungal drugs (e.g., voriconazole), and retinoids (69–74). Recently, reports suggest that pseudoporphyria can be induced by finasteride and imatinib mesylate (3,44).…”

Section: Pseudoporphyriamentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis of Common Dermopathies in Dialysis Patients: A Review and Update

Markova

Lester

Wang

et al. 2012

Seminars in Dialysis

View full text Add to dashboard Cite

Cutaneous abnormalities in patients with end-stage renal disease (ESRD) receiving hemodialysis or peritoneal dialysis may demonstrate signs of their underlying condition or reveal associated disease entities. While a thorough examination of the scalp, skin, mucosa, and nails is integral to establishing a diagnosis, certain conditions will resolve only with dialysis or improvement of their renal disease and others may not require or respond to treatment. Half and half nails, pruritus, xerosis, and cutaneous hyperpigmentation are common manifestations in ESRD. With hemodialysis, uremic frost is no longer prevalent in ESRD patients and ecchymoses have decreased in incidence. Acquired perforating dermatoses are seen in over one-tenth of hemodialysis patients. Metastatic calcinosis cutis and calciphylaxis are both rarely reported, although the latter is seen almost exclusively in the setting of hemodialysis. Diagnosis of nephrogenic systemic fibrosis has historically been challenging; as such, new diagnostic criteria have been proposed. Blood porphyrin profiles are needed to differentiate between porphyria cutanea tarda and pseudoporphyria. We will review and provide an update on the aforementioned common cutaneous manifestations of ESRD in patients receiving dialysis.

show abstract

Section: Calciphylaxis (Calcific Uremic Arteriolopathy)mentioning

confidence: 99%

Section: Pseudoporphyriamentioning

confidence: 99%

Diagnosis of Common Dermopathies in Dialysis Patients: A Review and Update

Markova

Lester

Wang

et al. 2012

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

“…Reported neurological (psychiatric) adverse events include: depression and anxiety; cognitive impairment; and suicidal ideation . Furthermore, several case studies have linked finasteride with male infertility (76)(77)(78)(79), cataract and intraoperative floppy-iris syndrome (80), pseudoporphyria (81), and T cell-mediated acute localized exanthematous pustulosis (82).…”

mentioning

confidence: 99%

Post-finasteride syndrome: a surmountable challenge for clinicians

Traish

2020

Fertility and Sterility

View full text Add to dashboard Cite

Post-finasteride syndrome (PFS) is a constellation of serious adverse side effects manifested in clinical symptoms that develop and persist in patients during and/or after discontinuing finasteride treatment in men with pattern hair loss (androgenetic alopecia) or benign prostatic hyperplasia. These serious adverse side effects include persistent or irreversible sexual, neurological, physical and mental side effects. To date, there are no evidence-based effective treatments for PFS. Although increasing number of men report persistent side effects, the medical community has yet to recognize this syndrome nor are there any specific measures to address this serious and debilitating symptoms. Here we evaluate the scientific and clinical evidence in the contemporary medical literature to address the very fundamental question: Is PFS a real clinical condition caused by finasteride use or are the reported symptoms only incidentally associated with but not caused by finasteride use? One key indisputable clinical evidence noted in all reported studies with finasteride and dutasteride was that use of these drugs is associated with development of sexual dysfunction, which may persist in a subset of men, irrespective of age, drug dose or duration of study. Also, increased depression, anxiety and suicidal ideation in a subset of men treated with these drugs were commonly reported in a number of studies. It is important to note that many clinical studies suffer from incomplete or inadequate assessment of adverse events and often limited or inaccurate data reporting regarding harm. Based on the existing body of evidence in the contemporary clinical literature, the author believes that finasteride and dutasteride induce a constellation of persistent sexual, neurological and physical adverse side effects, in a subset of men. These constellations of symptoms constitute the basis for PFS in individuals predisposed to epigenetic susceptibility. Indeed, delineating the pathophysiological mechanisms underlying PFS will be of paramount importance to the understanding of this syndrome and to development of potential novel therapeutic modalities. (Fertil Steril Ò 2020;113:21-50. Ó2019 by American Society for Reproductive Medicine.

show abstract

“…Pseudoporphyria was initially described with nalidixic acid, furosemide, and naproxen, predominantly in children 1 , but more recently, many other drugs have been associated with this phototoxic reaction: celecoxib 45 , ciprofloxacin 46 , voriconazole 47 , torasemide 48 , metformin 49 , finasteride 50 , and imatinib 51 .…”

Section: Subacute Patterns Of Drug Photosensitivitymentioning

confidence: 99%

Drug-induced photosensitivity

Gouveia

Gameiro

Coutinho

et al. 2023

PJDV

View full text Add to dashboard Cite

Drug photosensitivity is a relatively frequent adverse event, although not always recognized due to its clinical polymorphism and difficulties in performing tests to prove drug causality.The aim of this report is to review the mechanisms of photosensitivity related with topical and systemic drugs (phototoxicity, photoallergy, autoimmunity, and enhanced photocarcinogenesis), the main acute and delayed clinical manifestations (acute sunburn or eczema, pseudoporphyria, photo-onycholysis, dyschromia, telangiectasia, subacute lupus erythematosus, pre-cancerous lesions, and cutaneous neoplasia), the main culprits [non-steroidal anti-inflammatory drugs (NSAIDs), antimicrobials, like fluoroquinolones and tetracyclines, psychotropic, anticancer, and cardiovascular drugs] and the most adequate diagnostic procedures (photopatch and drug photoprovocation tests).

show abstract

Finasteride-Induced Pseudoporphyria

Cited by 16 publications

References 2 publications

Diagnosis of Common Dermopathies in Dialysis Patients: A Review and Update

Diagnosis of Common Dermopathies in Dialysis Patients: A Review and Update

Post-finasteride syndrome: a surmountable challenge for clinicians

Drug-induced photosensitivity

Contact Info

Product

Resources

About